The transaction, which builds on the companies’ long‑standing collaboration, will also give Sanofi a 26.4% equity stake in Cheplapharm.
Among the medicines being transferred is the high‑selling anticoagulant Lovenox/Clexane (enoxaparin), along with 19 other older, approved medicines whose names will be announced later.